drugset / Trial / NCT04269642
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is to evaluate the safety and efficacy of sustained release (SR)-Exenatide (PT320, Q1W and Q2W) in the treatment of patients with early Parkinson's disease (PD).
Timeline
- Start
- 2020-03-19
- Primary completion
- 2021-09-29
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 2 mg | Subcutaneous |
| Subject | Exenatide | Peptide | 2.5 mg | Subcutaneous |